Showing posts with label axxe small cap stock. Show all posts
Showing posts with label axxe small cap stock. Show all posts

Monday, August 30, 2010

StockProfiler.US: Small Cap Stock Market Picks for Monday: AXXE & POSC


MARKHAM, ON, Aug 26, 2010 -- Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they anticipate generating an additional $700,000 in annual sales from their pre-natal, non-constipating multi-vitamin Triferrex PN.

Axxess Pharma Inc. closed at $0.021 Friday, trading 74,500 shares.

Axxess Pharma Inc. Anticipates Additional $700,000 in Annual Sales From Pre-Natal, Non-Constipating Multi-Vitamin Triferrex PN

About Axxess Pharma Inc.

Axxess Pharma Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

INDIANAPOLIS, Aug 30, 2010 -- Positron Corporation (OTCBB: POSC) is pleased to announce K. Lance Gould M.D. as the keynote speaker for their upcoming cardiac PET symposium, held at the American Society of Nuclear Cardiology (ASNC) annual meeting, September 23-26 in Philadelphia, PA.

Positron Corporation closed at $0.061 Friday, trading 2,204,640 shares.

Positron to Host Cardiac PET Symposium at American Society of Nuclear Cardiology Annual Meeting; Renowned Cardiac Expert Dr. K. Lance Gould to be Keynote Speaker

About Positron

Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. More information about Positron is available at positron.com.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Thursday, August 26, 2010


MARKHAM, ON, Aug 26, 2010 -- Axxess Pharma Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they anticipate generating an additional $700,000 in annual sales from their pre-natal, non-constipating multi-vitamin Triferrex PN.

Axxess Pharma Inc. closed at $0.029 Wednesday, trading 795,653 shares.

Axxess Pharma Inc. Anticipates Additional $700,000 in Annual Sales From Pre-Natal, Non-Constipating Multi-Vitamin Triferrex PN

About Axxess Pharma Inc.

Axxess Pharma Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

BUENA PARK, CA, August 26, 2010 -- SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced that it has posted a 1,000 percent year-over-year increase in revenue for the second quarter ending June 30, 2010.

SOHM, Inc. closed at $0.0577 Wednesday, trading 794,490 shares.

SOHM Reports Consecutive Record Quarters With 1,000 Percent Year-Over-Year Revenue Increase for the Second Quarter 2010

About SOHM, Inc.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters are located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. sohm.com


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Friday, August 20, 2010

StockProfiler.US: Small Cap Pharmaceutical Companies AXXE & APHY


MARKHAM, ON, August 18, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, wishes to advise shareholders and other interested parties that Senior Management has become aware of an unauthorized press release being disseminated to the public by Mina Mar Marketing Group.

Axxess Pharma, Inc. closed at $0.015 Thursday, trading 24,300 shares.

Axxess Pharma, Inc. Reports Unauthorized and Inaccurate Press Release Distributed by Mina Mar Marketing Group

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

FRISCO, Texas, Aug. 19, 2010 -- Assured Pharmacy (PINKSHEETS: APHY), a leading specialty pharmacy providing prescription medications to more than 3,000 sufferers of chronic pain announced that total sales on a same store basis for the month of July 2010 were $1,422,163 which equates to $67,722 per business day.

Assured Pharmacy closed at $0.009 Thursday, trading 708,000 shares.

Assured Pharmacy Reports Same Store Sales for the Month of July 2010

About Assured Pharmacy, Inc.

Assured Pharmacy, Inc. is engaged in the business of operating specialty pharmacies that primarily dispense highly regulated pain medication. The Company derives its revenue primarily from the sale of prescription drugs and does not keep in inventory non-prescription drugs or health and beauty related products inventoried at traditional pharmacies. The Company offers physicians the ability to electronically transmit prescriptions to its pharmacies. The majority of the Company's business is derived from repeat business from its customers. "Walk-in" prescriptions from physicians are limited. The Company currently has four operating pharmacies. Three of those pharmacies are wholly owned and the Company has a 94.8% ownership interest in the other pharmacy.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Wednesday, August 18, 2010

StockProfiler.US: Small Cap Stock News Tips: Axxess Pharma, Inc. & UV Flu Technologies, Inc.


MARKHAM, ON, Aug 16, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to report they have generated $1.3 million in annual sales from their non-constipating multi-vitamin Triferrex 150.

Axxess Pharma, Inc. closed at $0.028 Tuesday, trading 150,000 shares.

Axxess Pharma, Inc. Reports $1.3 Million in Annual Sales From Non-Constipating Multi-Vitamin Triferrex 150

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

CENTERVILLE, MA, August 18, 2010 -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed an agreement with Trade Network, Inc., dba Creative Media and Buying Services, to produce a series of television advertisements in order to publicize a national awareness campaign featuring the ViraTech UV-400 product line, and its proven health benefits in relationship to the ongoing and growing dangers presented by poor indoor air quality in homes, and workplaces across the nation.

UV Flu Technologies, Inc. closed at $0.375 Tuesday, trading 78,153 shares.

UV Flu Technologies Plans National Television Sales Awareness Campaign

About UV Flu Technologies, Inc.

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector. The Company manufactures the VIRATECH UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Tuesday, August 17, 2010

StockProfiler.US: Tuesday's Pharmaceutical Company News Updates: Axxess Pharma, Inc. & Cypress Bioscience, Inc.


MARKHAM, ON, Aug 16, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to report they have generated $1.3 million in annual sales from their non-constipating multi-vitamin Triferrex 150.

Axxess Pharma, Inc. closed at $0.024 Monday, trading 1,234,168 shares.

Axxess Pharma, Inc. Reports $1.3 Million in Annual Sales From Non-Constipating Multi-Vitamin Triferrex 150

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

SAN DIEGO, CA, August 17, 2010 -- Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that its Board of Directors has sent a letter to Ramius LLC in response to Ramius' letter dated August 11, 2010.

Cypress Bioscience, Inc. closed at $3.81 Monday, trading 206,600 shares.

Cypress Bioscience Sends Letter to Ramius

About Cypress Bioscience

Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, Cypress has received multiple FDA approvals, including Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia. The Company focuses on generating shareholder value by reaching clinical development milestones as quickly and efficiently as possible. Cypress' currently marketed products include Savella and the Avise PG(SM) and Avise MCV(SM) therapeutic monitoring, diagnostic and prognostic testing services for rheumatoid arthritis. Development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, as well as AVISE-SLE(SM), a lupus diagnostic testing service. More information on Cypress and its products and development assets is available at cypressbio.com/.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Monday, August 16, 2010

StockProfiler.US: Small Cap Pharmaceutical Company News: Axxess Pharma, Inc. & A5 Laboratories Inc.


MARKHAM, ON, Aug 16, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to report they have generated $1.3 million in annual sales from their non-constipating multi-vitamin Triferrex 150.

Axxess Pharma, Inc. closed at $0.013 Friday, trading 332,829 shares.

Axxess Pharma, Inc. Reports $1.3 Million in Annual Sales From Non-Constipating Multi-Vitamin Triferrex 150

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

MONTREAL, QUEBEC, Aug. 16, 2010 -- A5 Laboratories Inc. (A5 Labs) (OTCBB: AFLB) today announced the appointment of Ms. Valentyna Navala to the position of Director of Microbiology and Interferon Clinical Programs and Mr. Chakib Rhofir to the position of Director of CRO Scientific Affairs.

Laboratories Inc. closed at $0.92 Friday, trading 158,490 shares.

A5 Laboratories Inc. Appoints Senior Managers

About A5 Labs

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

ONTARIO, CA, August 12, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, announces on June 14, 2010 Taylor Capitol, Inc was hired as Investor Relations to replace Mina Mar Marketing Group.

Axxess Pharma, Inc. closed at $0.013 Friday, trading 332,829 shares.

Axxess Pharma, Inc. Provides Update Regarding Mina Mar Marketing Group

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

FOOTHILL RANCH, CA, August 16, 2010 -- Medical Marijuana Inc (PINKSHEETS: MJNA) is pleased to announce progress as they move toward the launch date of August 28.

Medical Marijuana Inc closed at $0.09 Friday, trading 935,068 shares.

Medical Marijuana Inc Agent Base Continues to Expand With 12 Days Until Launch of "The Hemp Network," the World's First Hemp Product Related Network Marketing Company

About Medical Marijuana Inc.

Medical Marijuana Inc recognizes the vast and unequaled opportunities that exist in the rapidly expanding hemp and medical marijuana industries. The scientific recognition of cannabis has brought legalized marijuana use to the forefront of mainstream discussion, thus opening the door for safe and lucrative investment opportunities.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Friday, August 13, 2010

StockProfiler.US: Friday's Pharmaceutical Company Updates: Axxess Pharma, Inc. & Hana Biosciences Inc.


ONTARIO, CA, August 12, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription drugs, announces on June 14, 2010 Taylor Capitol, Inc was hired as Investor Relations to replace Mina Mar Marketing Group.

Axxess Pharma, Inc. closed at $0.0125 Thursday, trading 238,800 shares.

Axxess Pharma, Inc. Provides Update Regarding Mina Mar Marketing Group

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2010 -- Hana Biosciences Inc. (OTCBB: HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and six months ended June 30, 2010, and provided a corporate update.

Hana Biosciences Inc. closed at $0.13 Thursday, trading 2,060,629 shares.

Hana Biosciences Reports Second Quarter 2010 Financial Results

About Hana Biosciences, Inc.

Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The company's lead product candidate, Marqibo®, potentially treats acute lymphoblastic leukemia and lymphomas. The Company has additional pipeline opportunities some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. Additional information on Hana Biosciences can be found at hanabiosciences.com.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------

Wednesday, August 11, 2010

StockProfiler.US: Small Cap Pharmaceutical Company News Alerts: Axxess Pharma, Inc. & Advanced Life Sciences Holdings, Inc.


MARKHAM, ON, August 9, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce Health Canada approved 11 of their prescription and non-prescription drugs.

Axxess Pharma, Inc. closed at $0.008 Tuesday, trading 665,800 shares.

Axxess Pharma, Inc. Reports Health Canada Approves 11 Prescription and Non-Prescription Drugs

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

CHICAGO, Aug. 11, 2010 -- Advanced Life Sciences Holdings, Inc. (OTCBB: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2010.

Advanced Life Sciences Holdings, Inc. closed at $0.06 Tuesday, trading 5,179,833 shares.

Advanced Life Sciences Announces Second Quarter 2010 Financial Results

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at advancedlifesciences.com or follow us on twitter at twitter.com/advancedlifesci.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------
Keywords: axxe, axxe stock, axxe stock news, axxe stock alerts, axxe company news, axxe small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news updates, small cap stock profile

Monday, August 9, 2010

StockProfiler.US: Pharmaceutical Stock Picks on the Move: Axxess Pharma, Inc. & Cypress Bioscience, Inc.


ONTARIO, CA, August 5, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they have signed an exclusive license agreement to market and distribute a high potency, highly concentrated vitamin D-3 capsule.

Axxess Pharma, Inc. closed at $0.029 Friday, trading 336,000 shares.

Axxess Pharma, Inc. Signs Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 to Help Reduce Bone Loss and Joint Pain

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

SAN DIEGO, CA,  August 9, 2010 -- Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced financial results for the second quarter of 2010.

Cypress Bioscience, Inc. closed at $3.66 Friday, trading 1,126,000 shares.

Cypress Bioscience Announces Second Quarter 2010 Financial Results

About Cypress Bioscience, Inc.

Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, the Company has received multiple FDA approvals, including Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia. The Company focuses on generating shareholder value by reaching clinical development milestones as quickly and efficiently as possible. Cypress' currently marketed product is Savella. Development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, as well as AVISE-SLE(SM), a lupus diagnostic testing service. AVISE-SLE(SM) is included in the Company's personalized medicine services business, which the Company recently announced it intends to sell or cease operating by the end of the third quarter of 2010. More information on the Company and its products and development assets is available at http://www.cypressbio.com/.


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------
Keywords: axxe, axxe stock, axxe stock news, axxe stock alerts, axxe company news, axxe small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news updates, small cap stock profile

StockProfiler.US: Blazing Hot Pharmaceutical Small Cap Stocks: Axxess Pharma, Inc. & Nutra Pharma Corporation


MARKHAM, ON, August 9, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce Health Canada approved 11 of their prescription and non-prescription drugs.

Axxess Pharma, Inc. closed at $0.029 Friday, trading 336,000 shares.

Axxess Pharma, Inc. Reports Health Canada Approves 11 Prescription and Non-Prescription Drugs

About Axxess Pharma, Inc.

Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.

Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE


-------------------------------------------

CORAL SPRINGS, FL,  August 9, 2010 -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has selected Amarey Nova Medical S.A. to serve as the exclusive distributor in Colombia for its Nyloxin-branded pain relievers.

Nutra Pharma Corporation closed at $0.14 Friday, trading 3,943,181 shares.

Nutra Pharma Announces Amarey Nova Medical as Its Exclusive Nyloxin Distributor in Colombia

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Adrenomyeloneuropathy (AMN), Multiple Sclerosis (MS), and Human Immunodeficiency Virus (HIV). Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin and Nyloxin. For additional information about Nutra Pharma, visit: NutraPharma.com


-------------------------------------------

StockProfiler.US Announcement!

Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register

Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS

View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS

-------------------------------------------

About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------

Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.

This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.

Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.

To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer

-------------------------------------------
Keywords: axxe, axxe stock, axxe stock news, axxe stock alerts, axxe company news, axxe small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news updates, small cap stock profile